Shortened treatment for bloodstream yeast infection
Part of Infections clinical trials.
This study tests whether a shorter course of antifungal medication works as well as the standard longer course for patients with a yeast infection in the blood (candidemia) that is not complicated by spread to other organs. If you have cleared the infection from your blood and are fever-free, you may be able to stop treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a yeast infection in the blood that has not spread to your heart, eyes, brain, kidneys, or other deep organs
- Have a central line or catheter that can be removed if needed
- Be fever-free and have had at least one follow-up blood test showing the infection is gone
- Not currently have a weakened immune system that is expected to last more than 7 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of the antifungal caspofungin (7 days total) is as effective as the usual longer treatment for people with uncomplicated candidemia, a yeast infection in the blood. Participating patients must already be on caspofungin and have shown clear blood cultures for 7 days.
This study compares a shorter treatment (7 days) with the standard 14-day treatment for uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you qualify, you may receive the shorter treatment, which could be just as effective with fewer side effects.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
This study tests a shorter course of an antifungal medicine (fluconazole) for people with HIV who have a low level of a fungus called cryptococcus in their blood. The goal is to see if a shorter treatment works as well and to find the best time to start HIV medicines.
This trial tests a new antifungal drug, HRS9432, for patients with candidemia (a yeast infection in the blood) or invasive candidiasis (yeast infection in organs). It aims to see if the drug is safe and works well for these serious infections.
Hear when a new Candidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.